Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 14:15:1522392.
doi: 10.3389/fimmu.2024.1522392. eCollection 2024.

Targeting glycolysis: exploring a new frontier in glioblastoma therapy

Lu Yang  1 , Sijia Li  1 , Lei Yu  1 , Jiao Leng  1 , Na Li  1
Affiliations
Review

Targeting glycolysis: exploring a new frontier in glioblastoma therapy

Lu Yang et al. Front Immunol. .

Abstract

Glioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment options, including maximal safe surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, have limited efficacy.In recent years, the role of glycolytic metabolic reprogramming in GBM has garnered increasing attention. This review delves into the pivotal role of glycolytic metabolic reprogramming in GBM, with a particular focus on the multifaceted roles of lactate, a key metabolic product, within the tumor microenvironment (TME). Lactate has been implicated in promoting tumor cell proliferation, invasion, and immune evasion. Additionally, this review systematically analyzes potential therapeutic strategies targeting key molecules within the glycolytic pathway, such as Glucose Transporters (GLUTs), Monocarboxylate Transporters(MCTs), Hexokinase 2 (HK2), 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3), Pyruvate Kinase Isozyme Type M2 (PKM2), and the Lactate Dehydrogenase A (LDHA). These studies provide a novel perspective for GBM treatment. Despite progress made in existing research, challenges remain, including drug penetration across the blood-brain barrier, side effects, and resistance. Future research will aim to address these challenges by improving drug delivery, minimizing side effects, and exploring combination therapies with radiotherapy, chemotherapy, and immunotherapy to develop more precise and effective personalized treatment strategies for GBM.

Keywords: glioblastoma; glycolytic metabolic reprogramming; lactate; targeted therapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Glycolytic metabolic reprogramming in glioblastoma. GLUT, Glucose transporter; HK, Hexokinase 2; Glucose-6P, Glucose-6 phosphate; Fructose-6P, fructose-6-phosphate; PFK, Phosphofructokinase; fructose-1,6-bip, Fructose-1,6-biphosphate; GA3P, glyceraldehyde-3-phosphate; 2PG, 2-phosphoglycerate; PEP, Phosphoenolpyruvate; PKM2, Pyruvate Kinase 2; MCT, Monocarboxylate transporter. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. (2007) 114:97–109. doi: 10.1007/s00401-007-0243-4 - DOI - PMC - PubMed
    1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-oncology. (2019) 21:v1–v100. doi: 10.1093/neuonc/noz150 - DOI - PMC - PubMed
    1. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. Jama. (2015) 314:2535–43. doi: 10.1001/jama.2015.16669 - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. (2005) 352:987–96. doi: 10.1056/NEJMoa043330 - DOI - PubMed
    1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med. (2009) 360:765–73. doi: 10.1056/NEJMoa0808710 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources